Navigation Links
YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB PRESENTATIONS TO BE MADE AT THE 100TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH AND EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY
Date:3/13/2009

MISSISSAUGA, ON, March 13 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Alternext US:YMI, TSX:YM, AIM:YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today reported that its poster entitled, "Binding properties of the anti-EGFR monoclonal antibody, nimotuzumab, limit interaction with the EGFR in renal and epidermal cells", has been accepted for presentation at the American Association for Cancer Research's (AACR) 100th Annual Meeting in Denver, Colorado on April 20th, 2009 (Abstract # 2763; Hall B-F, Poster Section 31; Session ID: Clinical Research 10).

The abstract of this poster has been published today (09-AB-5492-AACR).

"Data to be presented at the AACR and ESMO conferences, combined with rash being reported independent of the KRAS status of patients, are in sharp contrast to the dated speculation that toxicity is a marker for efficacy of EGFR-targeting agents," said David Allan, Chairman and CEO of YM BioSciences. "The data we present show the monovalent binding to normal cells of other antibodies confirming that only nimotuzumab will avoid severe rash, hypomagnesemia and the other debilitating toxicities common with the marketed antibodies. Consequently, nimotuzumab's benign safety profile makes it the anti-EGFR agent of choice for chronic use."

The objectives of the study to be presented at AACR were to examine whether the cause of the toxicities seen with currently marketed anti-EGFR antibodies, particularly severe skin rash and hypomagnesemia, were the result of properties intrinsic to the individual antibodies or to the class. The results show that Erbitux(R) binds to normal cells because it is capable of monovalent binding to very low expressions of EGFR whereas nimotuzumab's monovalent binding is transient. It is this transient monovalent binding that results in its benign safety profile. Both antibodies bind definitively when binding bivalently.'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sangamo BioSciences Announces Presentations at Two Upcoming Investor Conferences
2. Hana Biosciences Announces New Positive Interim Efficacy Results in Pivotal rALLy Clinical Trial of Marqibo in Acute Lymphoblastic Leukemia
3. Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound
4. Cardio3 BioSciences Raises EUR13.7 Million in Series B Fundraising and Grant Funding
5. YM BioSciences Announces Milestone Payment For Approval Of Nimotuzumab In The Philippines And Indonesia
6. Sangamo BioSciences Provides Update on Companys 2008 Progress and 2009 Objectives
7. Chipscreen Biosciences and HUYA Bioscience Intl Announce Promising Preclincial and Phase I Solid Tumor/Lymphoma Data for Chidamide/HBI-8000, New HDAC Inhibitor for Cancer
8. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
9. Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting
10. Epiphany Biosciences to Continue Phase 2 Shingles Study After Interim Analysis; Plans Follow-On Clinical Trial Studying Post-Herpetic Neuralgia (PHN)
11. Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at American College of Gastroenterology Annual Scientific Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014  Breg, Inc., a premier ... launched the FreeRunner™ knee brace with new innovations ... patella mal-tracking return to active lifestyles.  FreeRunner,s patent-pending ... braces, providing support when patients need it most, ... don,t. Patellofemoral issues are the most ...
(Date:7/10/2014)... 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... completed the sale to Galderma of all rights to ... by Valeant for $1.4 billion in cash, pursuant to ... completed its acquisition of Galderma. "We ... to a company that is firmly committed to the ...
(Date:7/10/2014)... Mass. , July 10, 2014 Decision ... report awareness of the U.S. Food and Drug Administration,s ... new phosphate binder Velphoro, which was approved by the ... in chronic kidney disease (CKD) patients on dialysis. ... TreatmentTrends: Nephrology (US) Q2 2014 : ...
Breaking Medicine Technology:Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3
... The Medical Oncology Association of Southern California ... an agreement to work together to expand use ... costs of cancer care in Southern California. ... and distribution services to help health care professionals, ...
... The American Society of Bariatric Physicians (ASBP) is sad ... go out to his family, friends and fans.  The recent ... a contributing factor to his death are concerning and bring ... prescribed. While the specific details of Bubba ...
Cached Medicine Technology:Medical Oncology Association of Southern California, Cardinal Health Specialty Solutions Collaborate With Payors to Improve Quality, Costs, Accessibility of Cancer Care 2Medical Oncology Association of Southern California, Cardinal Health Specialty Solutions Collaborate With Payors to Improve Quality, Costs, Accessibility of Cancer Care 3Physicians Who Treat Obesity Respond to the News of Bubba Smith's Overdose 2
(Date:7/11/2014)... repaired knee Anterior Cruciate Ligament (ACL) happens all too ... the American Orthopaedic Society for Sports Medicine,s (AOSSM) Annual ... risk factors may minimize the chance of a future ... few risk factors such as, age, activity level and ... of re-injury," said lead author, Christopher C. Kaeding, MD ...
(Date:7/11/2014)... July 11, 2014 With the maturity ... requirements on comfort, the installation rate of Chinese car ... the installation rate exceeded 88% and the demand outnumbered ... the next few years, Chinese car electric window regulator ... 2017, the market size is expected to exceed 110 ...
(Date:7/11/2014)... Wild by Nature, a natural and organic supermarket ... opening a fifth store to be located in West Islip, ... the largest selections of wheat and gluten-free products available. With ... stores have become a one-stop shop for anyone who needs ... gluten intolerance, is a spectrum of disorders, including celiac disease, ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 B. E. Smith, ... providers, has been retained to lead a national chief ... in Bend, Ore. The top executive search firm ... placed more than 900 healthcare executives into organizations. , ... St. Charles Health System is the largest provider of medical ...
(Date:7/11/2014)... the experienced dressmaker in the world, has become one ... to beach wedding dresses . Recently, the firm ... in its online shop. Included in the new range ... has been considered as one of the best garment ... spokesman, BellasDress provides superb special occasion gowns and great ...
Breaking Medicine News(10 mins):Health News:China Car Electric Window Regulator Industry to Grow at CAGR of 10% to 2017 Says a New Research Report at ChinaMarketResearchReports.com 2Health News:China Car Electric Window Regulator Industry to Grow at CAGR of 10% to 2017 Says a New Research Report at ChinaMarketResearchReports.com 3Health News:China Car Electric Window Regulator Industry to Grow at CAGR of 10% to 2017 Says a New Research Report at ChinaMarketResearchReports.com 4Health News:Wild by Nature Opens New Location 2Health News:St. Charles Health System Retains B. E. Smith to Recruit New CNO 2Health News:St. Charles Health System Retains B. E. Smith to Recruit New CNO 3Health News:BellasDress Emerges As Popular Online Supplier Of 2014 Beach Wedding Dresses 2
... to treat kidney cancer also targets a genetic mutation active ... (AML), the most common and lethal form of adult leukemia, ... Center report in the Jan. 29 edition of the Journal ... clinical trial, the drug sorafenib reduced the median percentage of ...
... Enforce PROTONIX Patent -, MADISON, N.J., Jan. 29 ... Nycomed, today announced the U.S. launch of Wyeth,s,own generic ... of generic pantoprazole tablets in the U.S. by Teva ... version of PROTONIX,will be distributed by Prasco starting today., ...
... Funding for Bioscience Summer Internship Program Over ... ... Foundation today,awarded $6.5 million to the Translational Genomics Research Institute,(TGen) as ... TGen for the next 25 years. The program helps cultivate new,scientific ...
... 29 At an Election Day,candidate forum in Tampa, ... Mitt Romney told a crowd of the,organization,s conservative seniors ... Hillarycare is not the answer., "I am convinced ... issue and,get our citizens insured but do it in ...
... Nektar,Therapeutics, (Nasdaq: NKTR ) President and Chief ... the upcoming Merrill Lynch,Pharmaceutical, Biotechnology & Medical Device Conference ... on Tuesday, February 5, 2008 at 1:00 p.m.,ET., ... a live,audio-only Webcast through a link posted on the ...
... Zimmer Holdings, Inc.,(NYSE: ZMH ; SWX: ... it will be participating in Merrill Lynch,s 19th ... New York on,February 5, 2008, at 8:00 a.m. ... presentation can be accessed via Zimmer,s,Investor Relations website ...
Cached Medicine News:Health News:Kidney cancer drug attacks a major type of acute myeloid leukemia 2Health News:Kidney cancer drug attacks a major type of acute myeloid leukemia 3Health News:Wyeth Announces Launch of Own Generic Version of PROTONIX 2Health News:Wyeth Announces Launch of Own Generic Version of PROTONIX 3Health News:Helios Education Foundation Invests $6.5 Million in New Partnership with TGen 2Health News:Helios Education Foundation Invests $6.5 Million in New Partnership with TGen 3Health News:Helios Education Foundation Invests $6.5 Million in New Partnership with TGen 4
... Operation: , Double Burst : 2 60-ms bursts of ... s (1 pulse/s) , Tetanus: 50 Hz (50 ... Single (4 pulses/2 s) , Output Current: Adjustable from ... pulses (200-us duration) , Indicators: Battery LED (green) indicates ...
... of Operation: , Standby: A standby switch maintains ... , Twitch: 1 s (1 pulse/s) , ... (4 pulses/2 s) , Output Current: Adjustable from ... Monophasic pulses (200-us duration) , Indicators: Battery LED ...
Anesthesia Associates Model 100 Compact Peripheral Nerve Stimulator, incorporates the latest state-of-the-art electronics with solid state cicuitry to ensure trouble-free operation and extended batte...
... the newest peripheral nerve stimulator from B. Braun ... stimulators providing advanced digital technology. , ,Your ... HNS11 allows the localization of practically all mixed ... ,An additional optional component for the HNS11 ...
Medicine Products: